Sales 2024 * | 55.19B 50.85B 4,338B | Sales 2025 * | 58.07B 53.51B 4,565B | Capitalization | 276B 254B 21,698B |
---|---|---|---|---|---|
Net income 2024 * | 7.74B 7.13B 608B | Net income 2025 * | 10.56B 9.73B 830B | EV / Sales 2024 * | 6.05 x |
Net Debt 2024 * | 57.92B 53.37B 4,553B | Net Debt 2025 * | 49.21B 45.34B 3,868B | EV / Sales 2025 * | 5.6 x |
P/E ratio 2024 * |
30.3
x | P/E ratio 2025 * |
23.4
x | Employees | - |
Yield 2024 * |
3.99% | Yield 2025 * |
4.16% | Free-Float | 96.38% |
Latest transcript on AbbVie
Managers | Title | Age | Since |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 31/12/12 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 31/12/12 |
Robert Michael
PSD | President | 53 | 31/12/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 31/12/12 |
Edward Rapp
BRD | Director/Board Member | 66 | 31/12/12 |
Director/Board Member | 70 | 31/12/12 |
1st Jan change | Capi. | |
---|---|---|
+39.82% | 734B | |
+32.70% | 591B | |
-7.31% | 350B | |
+14.23% | 315B | |
+14.21% | 238B | |
-6.30% | 204B | |
+8.74% | 206B | |
+4.51% | 161B | |
-2.05% | 160B |